Eysuvis — CareFirst (Caremark)
Short-term treatment of signs and symptoms of dry eye disease
Initial criteria
- The requested drug is being prescribed for the treatment of dry eye disease AND the request is for Eysuvis AND the requested drug is being prescribed for short-term use (up to two weeks).
Reauthorization criteria
- All patients (including new patients) requesting authorization for continuation of therapy for Eysuvis must meet ALL requirements in the coverage criteria section.
Approval duration
3 months